Today: 25 January 2026
Subscribe
Browse Category

EPA:ABVX.PA News 8 January 2026 - 12 January 2026

Abivax stock jumps on fresh Eli Lilly takeover talk as ABVX.PA hits record — what traders watch next

Abivax stock jumps on fresh Eli Lilly takeover talk as ABVX.PA hits record — what traders watch next

Paris, Jan 12, 2026, 11:17 CET — Regular session Shares in ABIVAX Société Anonyme surged Monday following a French media report that stirred new takeover speculation involving the biotech and U.S. pharmaceutical giant Eli Lilly. (Reuters) The stock climbed roughly 22% to 120.60 euros, hitting a peak of 130 euros earlier, based on Euronext-tracked quotes. It closed at 99 euros…
12 January 2026
····
Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

PARIS, Jan 8, 2026, 20:02 (CET) — Market closed Shares in French biotech Abivax SA (ABVX.PA) closed down 9.49% at 99.20 euros on Thursday, after swinging between 112.40 euros at the open and a low of 94.20 euros. The stock slipped back under the 100-euro mark, with volume at about 246,000 shares, after a 6% rise the day before. MarketScreener…
8 January 2026
·····

Stock Market Today

  • Bunzl Shares Down 37% in a Year Despite EPS Growth
    January 25, 2026, 3:34 AM EST. Bunzl plc (LON:BNZL) investors have faced a 37% loss over the past year, while the market returned 25%. The company's share price declined 39% over 12 months and has fallen 14% in the last three months. Over three years, shares are down 31%. Despite the price drop, earnings per share (EPS) rose 0.7% in the same period, suggesting market expectations for higher growth were unmet. Revenue remained steady, possibly fueling disappointment. Insider buying has been noted, indicating confidence within the company. Long-term shareholders have experienced a modest annual loss of 0.3% over five years. Analysts will watch future earnings closely to determine if a turnaround is feasible amid continued share price weakness.
Go toTop